Founded in 1991, Myriad Genetics pioneered the market for hereditary cancer testing with the discovery of the BRCA1 and BRCA2 genes and the subsequent launch of its BRACAnalysis test. Today, the company operates through three primary business segments: Oncology, Women's Health, and Mental Health. Its product portfolio includes the MyRisk Hereditary Cancer Test, the Prolaris prostate cancer test, the GeneSight psychotropic medication test, and various prenatal screening solutions. By leveraging proprietary technologies and data analytics, Myriad provides healthcare professionals with actionable molecular insights to improve patient care and clinical outcomes. The company primarily serves the United States market while expanding its international reach through strategic partnerships.
